ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Gabapentin

Also written as “gabapentin”, “gabapentin 600 mg” and “Gabapentin Extended Release tablets”.

Its studies are mostly in Sleep Initiation and Maintenance Disorders · Hot Flashes · Diabetic Neuropathies · Epilepsies, Partial · Neuralgia, Postherpetic, led by 8 companies.

Drug pageGabapentin: every studyMany companies study it; this page follows only the 44 they lead. All 334 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 28, 200744 company-led studies, 1 open or runningNext primary completion: Jan 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatrisits history only201 open or runningphase 4since Sep 28, 2007Sep 8, 2005Jan 31, 2027phase 4 · NCT07813026
Depomed80 open or runningphase 4since Jun 5, 2017Jun 8, 2006none ahead
Teva Pharmaceutical Industriesits history only60 open or runningphase 1since Mar 17, 2009Mar 17, 2009none ahead
Sun Pharmaceutical Industriesits history only40 open or runningno phasesince Oct 22, 2008Oct 22, 2008none ahead
GlaxoSmithKlineits history only20 open or runningphase 1since Sep 29, 2011Sep 29, 2011none ahead
Pharmaceutical Research Management srlits history only20 open or runningphase 3since Mar 18, 2016Mar 18, 2016none ahead
Nang Kuang Pharmaceuticalits history only10 open or runningphase 4since Feb 24, 2014Feb 24, 2014none ahead
Pfizerits history only10 open or runningphase 1since May 5, 2010May 5, 2010none ahead

Also a collaborator on its studies: Chiltern International and Boehringer Ingelheim.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Depomed only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 8, 2006First study: phase 3 study in Neuralgia, PostherpeticFirst studyNCT00335933 · 378 enrolled · United States
  2. Aug 2, 2007Phase 2 study in Hot FlashesNCT00511953 · 108 enrolled · United States
  3. Feb 21, 2008Phase 3 study in Neuralgia, PostherpeticNCT00636636 · 452 enrolled · United States, Argentina, Russian Federation
  4. Jul 8, 2008Phase 2 study in PainNCT00712439 · 147 enrolled
  5. Sep 17, 2008Phase 3 study in Hot FlashesNCT00755417 · 541 enrolled · United States
  6. Oct 21, 2008Phase 3 study in Hot FlashesNCT00777023 · 565 enrolled · United States
  7. Mar 2, 2010Phase 3 study in Hot FlashesNCT01080300 · 600 enrolled · United States
  8. Jun 5, 2017Phase 4 study in HealthyNCT03179345 · 32 enrolled

TargetBeta

“Voltage-gated calcium channel modulator”ChEMBL 37, by rule

Other programs on the same 26 targets

ProgramCompanyFurthest phaseStudies
PregabalinruleViatrisphase 4149

Studies

All 8 Depomed leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03179345Healthy4CompletedNov 20, 201532
NCT01080300Hot Flashes · United States3CompletedSep 2011600
NCT00777023Hot Flashes · United States3CompletedJul 2009565
NCT00755417Hot Flashes · United States3CompletedAug 2009541
NCT00712439Pain2CompletedNov 2006147
NCT00636636Neuralgia, Postherpetic · United States, Argentina, Russian Federation3CompletedAug 2009452
NCT00511953Hot Flashes · United States2CompletedDec 2007108
NCT00335933Neuralgia, Postherpetic · United States3Completed378

How it is read

Names in the registry

  • “Gabapentin”, 27 entries
  • “gabapentin”, 5 entries
  • “gabapentin 600 mg”, 3 entries
  • “Gabapentin Extended Release tablets”, 3 entries
  • “Gabapentin 800 mg tablets, single dose (1 tablet)”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.